CC-10004 for Prurigo Nodularis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2009 by University Hospital Case Medical Center.
Recruitment status was  Recruiting
Celgene Corporation
Information provided by:
University Hospital Case Medical Center Identifier:
First received: March 23, 2009
Last updated: January 11, 2010
Last verified: March 2009

This trial will include:

  • Study period up to 7 months.
  • Office visits monthly lasting approximately 1 hour.
  • Blood Draws.
  • Oral medication that is taken 2 times daily.
  • Photographs and biopsies if agreed.

Condition Intervention Phase
Prurigo Nodularis
Drug: CC-10004
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label, Single Center Study to Assess the Safety and Efficacy of a 24 Week Treatment Course of CC-10004 in Adults With Recalcitrant Nodularis

Resource links provided by NLM:

Further study details as provided by University Hospital Case Medical Center:

Primary Outcome Measures:
  • Determine the effect on patient pruritus as measure by the Visual Analog Scale for Prurtis [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 15
Study Start Date: March 2008
Estimated Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: CC-10004
    30mg, BID, for 24 weeks

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must understand and voluntarily sign an informed consent form
  • Must be male or female and aged ≥ 18 years at time of consent
  • Must be able to adhere to the study visit schedule and other protocol requirements
  • Must have a diagnosis of prurigo nodularis based on clinical and histological findings and have failed four weeks of treatment with topical therapies, including corticosteroids and/or vitamin D derivatives.
  • Must meet the following laboratory criteria:

    • Hemoglobin WNL
    • Hematocrit WNL
    • White blood cell (WBC) count WNL
    • Neutrophils ≥ 1500 /dL
    • Platelets ≥ 100,000 /dL
    • Serum creatinine ≤ 1.5 mg/dL
    • Total bilirubin 2.0 mg/dL
    • Aspartate transaminase (AST [serum glutamic oxaloacetic transaminase, SGOT]) and alanine transaminase (ALT [serum glutamate pyruvic transaminase, SGPT]) 1.5x upper limit of normal (ULN)
  • Females of childbearing potential (FCBP) must have a negative urine pregnancy test at screening (Visit Must have a negative purified protein derivative (PPD) within 28 days of the baseline visit.
  • Must have a negative purified protein derivative (PPD) within 28 days of the baseline visit.

Exclusion Criteria:

  • History of cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic, or other major diseases deemed clinically significant by the investigator
  • Any systemic treatment (including ultraviolet light, corticosteroids, thalidomide, azathioprine, cyclosporine) within 28 days of study drug administration.
  • Any topical treatments (including corticosteroids, vitamin D derivatives) within 14 days of study drug initiation.
  • Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
  • Pregnant or lactating female.
  Contacts and Locations
Please refer to this study by its identifier: NCT00869089

Contact: Kelly Jeffords, CCRC 216-983-0861
Contact: Mary Ann Smith, RN 216-844-7164

United States, Ohio
University Hospital Case Medical Center Recruiting
Cleveland, Ohio, United States, 44106
Contact: Kelly Jeffords, CCRC    216-983-0861   
Sponsors and Collaborators
University Hospital Case Medical Center
Celgene Corporation
Principal Investigator: Neil Korman, M.D.,PhD. University Hospital Case Medical Center
  More Information

No publications provided

Responsible Party: Neil Korman, M.D., PhD., University Hospitals Case Medical Center Identifier: NCT00869089     History of Changes
Other Study ID Numbers: 102652, 12-07-24
Study First Received: March 23, 2009
Last Updated: January 11, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by University Hospital Case Medical Center:

Additional relevant MeSH terms:
Skin Diseases
Skin Diseases, Eczematous processed this record on April 16, 2014